Tucotuzumab celmoleukin

DB15402InvestigationalProtein Based Therapies

Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous...

Mechanism: Pharmacologically active on Epithelial cell adhesion molecule
Curator reviewed

Resolves to

Compound

UNII4ON7FF680UCAS339986-90-2

Targets

P16422EPCAM

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tucotuzumab celmoleukin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account